Abstract:Celastrol was originally identified from traditional Chinese medicine Tripterygium wilfordii decades ago and used for the treatment of cancer and inflammatory diseases. Beside its superior antitumor capabilities, the underlying mechanism of the anti-tumor activity of celastrol was also mentioned, including through modulating proteasome activity, heat shock response, and NF-κB signaling pathways. Some of these reports also mentioned the ability of celastrol to inhibit tumor metastasis; nevertheless, to date, no study has described its anti-metastatic activities comprehensively, or characterized the underlying mechanisms profoundly. In the current study, for the first time, we systematically evaluated the effects of celastrol represented in metastatic-related events including cell-ECM adhesion, migration, invasion, and development of pulmonary metastases in vivo, using corresponding assays and models. Addtionally, we revealed that celastrol inhibited the integrin-mediated Mice melanoma cell B16F10 and human lung cancer cell 95-D cell-ECM adhesion and spreading partially via p38 MAPK Pathway, which also contributed to its antimetastatic effect. Celastrol inhibited 95-D and B16F10 cells adhesion to fibronectin in a dose-dependent manner. When 4 μM of celastrol was applied on 95-D cells, the ratio of cell adhesion was declined to 41% from 100%; similarly, celastrol (8 μM) down-regulated the B16F10 cell adhesion to fibronectin from 100% to 23%. On the contrary, the cell adhesion to poly-l-lysine (PLL), an event did not engage with integrin, was not affected upon celastrol treatment. The formation of focal adhesions was also disrupted by celastrol. Western blot and immunofluorescence assay declared that this inhibition was achieved through suppressing β1 integrin ligand affinity, focal adhesion formation, accompanied with the reduced phosphorylation of focal adhesion kinase (FAK). In understanding the underlying mechanisms, we found that celastrol activated p38 mitogen-activated protein kinase (MAPK) by phosphorylation prior to the decrement of phosphorylated FAK, and was independent on the presence of fibronectin. Using SB203580, a specific inhibitor of p38 MAPK, the effects of celastrol on β1 integrin function, cell-ECM adhesion, and phosphorylation of FAK were partially attenuated. Furthmore, focal adhesion-dependent cell migration and invasion were both inhibited by treatment with celastrol. Finally, the anti-metastatic activity of celastrol was examined in vivo using B16F10-GFP injected C57BL/6 mice model, as indicated by decreased pulmonary metastases in celastrol-administrated mice. Collectivly, these data not only demonstrates that celastrol exerts potent anti-metastasis activity both in vitro and in vivo, but also provides new evidences for the critical roles of p38 MAPK in the regulation of integrin function and cell adhesion. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3598.

Influence of long-term arotinolol treatment on myocardial mechanics and ventricular myosin isoenzymes in spontaneously hypertensive rats.

Celastrol Inhibits Cancer Metastasis by Suppressing M2-like Polarization of Macrophages.

Celastrol Acts As a Potent Antimetastatic Agent Targeting Β1 Integrin and Inhibiting Cell-Extracellular Matrix Adhesion, in Part Via the P38 Mitogen-Activated Protein Kinase Pathway

Abstract 3598: Targeting b1 integrin, celastrol as a potent anti-metastatic agent, inhibits cell-ECM adhesion, partially via the p38 MAPK pathway

Association between Bcl-2 expression and tumor recurrence in cervical cancer: a matched case-control study.

Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.

Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway

Celastrol Induces Apoptosis in Non-Small-Cell Lung Cancer A549 Cells Through Activation of Mitochondria- and Fas/Fasl-Mediated Pathways

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis

Celastrol suppresses human pancreatic cancer via m6A-YTHDF3-mediated downregulation of Claspin and Bcl-2

Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol's Anti-Tumor Angiogenesis Effect

Celastrol Prevents Atherosclerosis Via Inhibiting Lox-1 and Oxidative Stress

Celastrol Elicits Antitumor Effects by Inhibiting the STAT3 Pathway Through ROS Accumulation in Non-Small Cell Lung Cancer

Radiosensitizing Effect of Celastrol by Inhibiting G2/M Phase Arrest Induced by the C-Myc Gene of Human SW1353 Chondrosarcoma Cells: Network and Experimental Analyses.

Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity

NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis

Celastrol Induces Apoptosis and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells: an in Vitro and in Vivo Study

Potential Anticancer Effect of Celastrol on Hepatocellular Carcinoma by Suppressing CXCR4-related Signal and Impeding Tumor Growth in Vivo

Celastrol Induces Apoptosis of HT29 Cells through Inhibiting miR-21 Regulation of Bcl-2 Expression

ER Stress-Mediated Apoptosis Induced by Celastrol in Cancer Cells and Important Role of Glycogen Synthase Kinase-3 Β in the Signal Network